Evidence map›Paper›PMID 28818855›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2017

Paradigm of Biased PAR1 (Protease-Activated Receptor-1) Activation and Inhibition in Endothelial Cells Dissected by Phosphoproteomics.

Bart L van den Eshof, Arie J Hoogendijk, Pelle J Simpson, Floris P J van Alphen, Sara Zanivan, Koen Mertens, Alexander B Meijer, Maartje van den Biggelaar

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. The vascular endothelium as decision maker in lung injury.Frontiers in cell and developmental biology · 2025
    Review
  6. Endothelial protease-activated receptor 4: impotent or important?Frontiers in cardiovascular medicine · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Protease Activity in Vascular Disease.Arteriosclerosis, thrombosis, and vascular biology · 2019
    Review
  19. Review
  20. Reporting Sex and Sex Differences in Preclinical Studies.Arteriosclerosis, thrombosis, and vascular biology · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Bart L van den EshofFrom the Department Plasma Proteins (B.L.v.d.E., A.J.H., P.J.S., K.M., A.B.M., M.v.d.B.), Department of Research Facilities (F.P.J.v.A., A.B.M.), Sanquin Research, Amsterdam, The Netherlands; Tumour Microenvironment and Proteomics Laboratory, Cancer Research UK Beatson Institute, Glasgow, United Kingdom (S.Z.); Tumour Microenvironment and Proteomics Laboratory, Institute of Cancer Sciences, University of Glasgow, United Kingdom (S.Z.); Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands (K.M., A.B.M.).
Arie J HoogendijkFrom the Department Plasma Proteins (B.L.v.d.E., A.J.H., P.J.S., K.M., A.B.M., M.v.d.B.), Department of Research Facilities (F.P.J.v.A., A.B.M.), Sanquin Research, Amsterdam, The Netherlands; Tumour Microenvironment and Proteomics Laboratory, Cancer Research UK Beatson Institute, Glasgow, United Kingdom (S.Z.); Tumour Microenvironment and Proteomics Laboratory, Institute of Cancer Sciences, University of Glasgow, United Kingdom (S.Z.); Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands (K.M., A.B.M.).
Pelle J SimpsonFrom the Department Plasma Proteins (B.L.v.d.E., A.J.H., P.J.S., K.M., A.B.M., M.v.d.B.), Department of Research Facilities (F.P.J.v.A., A.B.M.), Sanquin Research, Amsterdam, The Netherlands; Tumour Microenvironment and Proteomics Laboratory, Cancer Research UK Beatson Institute, Glasgow, United Kingdom (S.Z.); Tumour Microenvironment and Proteomics Laboratory, Institute of Cancer Sciences, University of Glasgow, United Kingdom (S.Z.); Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands (K.M., A.B.M.).
Floris P J van AlphenFrom the Department Plasma Proteins (B.L.v.d.E., A.J.H., P.J.S., K.M., A.B.M., M.v.d.B.), Department of Research Facilities (F.P.J.v.A., A.B.M.), Sanquin Research, Amsterdam, The Netherlands; Tumour Microenvironment and Proteomics Laboratory, Cancer Research UK Beatson Institute, Glasgow, United Kingdom (S.Z.); Tumour Microenvironment and Proteomics Laboratory, Institute of Cancer Sciences, University of Glasgow, United Kingdom (S.Z.); Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands (K.M., A.B.M.).
Sara ZanivanFrom the Department Plasma Proteins (B.L.v.d.E., A.J.H., P.J.S., K.M., A.B.M., M.v.d.B.), Department of Research Facilities (F.P.J.v.A., A.B.M.), Sanquin Research, Amsterdam, The Netherlands; Tumour Microenvironment and Proteomics Laboratory, Cancer Research UK Beatson Institute, Glasgow, United Kingdom (S.Z.); Tumour Microenvironment and Proteomics Laboratory, Institute of Cancer Sciences, University of Glasgow, United Kingdom (S.Z.); Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands (K.M., A.B.M.).
Koen MertensFrom the Department Plasma Proteins (B.L.v.d.E., A.J.H., P.J.S., K.M., A.B.M., M.v.d.B.), Department of Research Facilities (F.P.J.v.A., A.B.M.), Sanquin Research, Amsterdam, The Netherlands; Tumour Microenvironment and Proteomics Laboratory, Cancer Research UK Beatson Institute, Glasgow, United Kingdom (S.Z.); Tumour Microenvironment and Proteomics Laboratory, Institute of Cancer Sciences, University of Glasgow, United Kingdom (S.Z.); Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands (K.M., A.B.M.).
Alexander B MeijerFrom the Department Plasma Proteins (B.L.v.d.E., A.J.H., P.J.S., K.M., A.B.M., M.v.d.B.), Department of Research Facilities (F.P.J.v.A., A.B.M.), Sanquin Research, Amsterdam, The Netherlands; Tumour Microenvironment and Proteomics Laboratory, Cancer Research UK Beatson Institute, Glasgow, United Kingdom (S.Z.); Tumour Microenvironment and Proteomics Laboratory, Institute of Cancer Sciences, University of Glasgow, United Kingdom (S.Z.); Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands (K.M., A.B.M.).
Maartje van den BiggelaarFrom the Department Plasma Proteins (B.L.v.d.E., A.J.H., P.J.S., K.M., A.B.M., M.v.d.B.), Department of Research Facilities (F.P.J.v.A., A.B.M.), Sanquin Research, Amsterdam, The Netherlands; Tumour Microenvironment and Proteomics Laboratory, Cancer Research UK Beatson Institute, Glasgow, United Kingdom (S.Z.); Tumour Microenvironment and Proteomics Laboratory, Institute of Cancer Sciences, University of Glasgow, United Kingdom (S.Z.); Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands (K.M., A.B.M.). m.vandenbiggelaar@sanquin.nl.
Cancer Research UK Scotland Institute · GBUniversity of Glasgow · GB

Funding

Cancer Research UK 12935Cancer Research UK 29800
6 · The paper itself

Abstract

objectiveThrombin is the key serine protease of the coagulation cascade and mediates cellular responses by activation of PARs (protease-activated receptors). The predominant thrombin receptor is PAR1, and in endothelial cells (ECs), thrombin dynamically regulates a plethora of phosphorylation events. However, it has remained unclear whether thrombin signaling is exclusively mediated through PAR1. Furthermore, mechanistic insight into activation and inhibition of PAR1-mediated EC signaling is lacking. In addition, signaling networks of biased PAR1 activation after differential cleavage of the PAR1 N terminus have remained an unresolved issue. APPROACH AND

resultsHere, we used a quantitative phosphoproteomics approach to show that classical and peptide activation of PAR1 induce highly similar signaling, that low thrombin concentrations initiate only limited phosphoregulation, and that the PAR1 inhibitors vorapaxar and parmodulin-2 demonstrate distinct antagonistic properties. Subsequent analysis of the thrombin-regulated phosphosites in the presence of PAR1 inhibitors revealed that biased activation of PAR1 is not solely linked to a specific G-protein downstream of PAR1. In addition, we showed that only the canonical thrombin PAR1 tethered ligand induces extensive early phosphoregulation in ECs.

conclusionsOur study provides detailed insight in the signaling mechanisms downstream of PAR1. Our data demonstrate that thrombin-induced EC phosphoregulation is mediated exclusively through PAR1, that thrombin and thrombin-tethered ligand peptide induce similar phosphoregulation, and that only canonical PAR1 cleavage by thrombin generates a tethered ligand that potently induces early signaling. Furthermore, platelet PAR1 inhibitors directly affect EC signaling, indicating that it will be a challenge to design a PAR1 antagonist that will target only those pathways responsible for tissue pathology.

Indexed as

Platelet Aggregation InhibitorsEndothelial CellsHumansLactonesPhosphorylationProteomicsPyridinesReceptor, PAR-1Signal TransductionLactonesPlatelet Aggregation InhibitorsPyridinesReceptor, PAR-1vorapaxarendothelial cellsmass spectrometryphosphorylationplatelet aggregation inhibitorsproteomicsreceptors, protease-activatedthrombin

Identifiers

PMID28818855
OpenAlexW2746765114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.